Uncertainties in value per statistical life estimates impact the extent to which COVID-19 policies yield net benefits.
EPA’s advance notice raises fundamental questions about how the agency should weigh costs and benefits.
Deregulatory executive orders require a new approach to analyzing regulatory impact.
Although agencies have made strides concerning values for mortality risk reductions, more research is needed on these values.
EPA’s Science Advisory Board offers recommendations to improve cost-benefit analysis.